Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2023-07-27 00:00:00+00:00 | ABBV | AbbVie raises annual profit forecast as Humira stays strong, new drugs impress | July 27 (Reuters) - AbbVie ABBV.N on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments.
Global Humira sales tumbled 25.2% to $4.01 billion compared with... |
2023-07-27 00:00:00+00:00 | ABBV | Stocks Climb Before the Open as Investors Await Key U.S. GDP Data, Meta Results Boost Sentiment | September S&P 500 futures (ESU23) are up +0.59%, and September Nasdaq 100 E-Mini futures (NQU23) are up +1.20% this morning after three major U.S. benchmark indices ended the regular session mixed as market participants digested Federal Reserve Chair Jerome Powell’s comments following the Fed’s widely expected 25 basis... |
2023-07-27 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-07-26 00:00:00+00:00 | ABBV | 3 Stocks to Buy While They Are on Sale | There's one main downside to the tremendous performance of the stock market so far in 2023. Many stocks are now priced for perfection. And unfortunately, perfection is rarely attainable.
The good news, though, is that not every stock has a sky-high valuation. Some are actually available at bargain prices. Here are thre... |
2023-07-26 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights Toyota, Deere, Starbucks, AbbVie and DexCom | For Immediate Release
Chicago, IL – July 26, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Toyota Motor Corp. TM, Deere ... |
2023-07-26 00:00:00+00:00 | ABBV | Looking to Get Richer? These 2 Dividend Stocks Have Doubled in 5 Years | As an investment class, dividend growth stocks tend to produce better investment outcomes than their non-dividend growth counterparts. This shouldn't come as a surprise considering that consistently handing out dividend raises requires growing profits, which leads to share price appreciation over time.
Here are two div... |
2023-07-26 00:00:00+00:00 | ABBV | PREVIEW-AbbVie may see less pain from Humira sales decline as rival lags | By Leroy Leo
July 26 (Reuters) - AbbVie Inc ABBV.N is likely to beat Wall Street sales estimates for Humira in the second quarter as the only copycat in the U.S. market for the blockbuster arthritis drug struggled to gain traction.
Humira sales are likely to decline when the company reports on Thursday but that would m... |
2023-07-26 00:00:00+00:00 | ABBV | Pre-Market Earnings Report for July 27, 2023 : MA, ABBV, MCD, LIN, CMCSA, HON, SPGI, BMY, AMT, HCA, BSX, NOC | The following companies are expected to report earnings prior to market open on 07/27/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
Mastercard Incorporated (MA)is reporting for the quarter ending June 30, 2023. The financial transactions company's consensus earnings per share forecas... |
2023-07-25 00:00:00+00:00 | ABBV | ABBV Quantitative Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-07-25 00:00:00+00:00 | ABBV | Zacks Investment Ideas feature highlights: Chipotle Mexican Grill, Visa and AbbVie | For Immediate Release
Chicago, IL – July 25, 2023 – Today, Zacks Investment Ideas feature highlights Chipotle Mexican Grill CMG, Visa V and AbbVie ABBV.
3 Non-Tech Reports to Watch This Week
Earnings season is rapidly picking up pace, with a wide variety of companies scheduled to unveil quarterly results this week.
And... |
2023-07-25 00:00:00+00:00 | ABBV | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)? | If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the Invesco Dynamic Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on 06/23/2005.
Retail and institutional investors increasingly turn to passively managed ETFs because they... |
2023-07-25 00:00:00+00:00 | ABBV | AbbVie's RINVOQ Gets Regulatory Nod In Canada For Yet Another Indication | (RTTNews) - AbbVie Inc. (ABBV) announced on Tuesday that RINVOQ, an oral, once-daily selective and reversible JAK inhibitor, has been approved for one more indication by Health Canada.
The drug has now been received approval in Canada to treat adults with moderately to severely active ulcerative colitis who have demons... |
2023-07-25 00:00:00+00:00 | ABBV | Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline | Pfizer (PFE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that co... |
2023-07-25 00:00:00+00:00 | ABBV | Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales? | AbbVie’s ABBV second-quarter revenues are likely to be driven by product revenues generated from its newer immunology drugs, Rinvoq and Skyrizi.
Around half of the company’s revenues is expected to be generated from its immunology franchise, consisting of three blockbuster drugs — Humira, Rinvoq and Skyrizi. Humira, wh... |
2023-07-25 00:00:00+00:00 | ABBV | William Blair Initiates Coverage of Abbvie (ABBV) with Market Perform Recommendation | Fintel reports that on July 25, 2023, William Blair initiated coverage of Abbvie (NYSE:ABBV) with a Market Perform recommendation.
Analyst Price Forecast Suggests 17.60% Upside
As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The forecasts range from a low of 136.35 to a high of $204.75. The ... |
2023-07-25 00:00:00+00:00 | ABBV | Q2 Earnings Season Scorecard and Analyst Reports for Toyota, Deere & Starbucks | Tuesday, July 25, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features a real-time update on the ongoing Q2 earnings season and new research reports on 16 major stocks, including Toyota Motor Corporation (TM), Deere & Company (DE) and Starbucks Corporatio... |
2023-07-24 00:00:00+00:00 | ABBV | Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now? | Making its debut on 03/03/2005, smart beta exchange traded fund Invesco Dynamic Large Cap Value ETF (PWV) provides investors broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
For a long time now, the ETF industry has been flooded with products based on market capitaliza... |
2023-07-24 00:00:00+00:00 | ABBV | 3 Non-Tech Reports to Watch This Week | Earnings season is rapidly picking up pace, with a wide variety of companies scheduled to unveil quarterly results this week.
And next week, we’ll have an even bigger slate.
On the minds of many this week is big tech earnings, with several heavyweights slated to report.
While many remain focused on tech, there are seve... |
2023-07-24 00:00:00+00:00 | ABBV | The 7 Best Dividend Stocks to Protect Your Portfolio From Global Chaos | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Although the best dividend stocks for portfolio protection might come off as a rather boring endeavor, at the present juncture, there may be no more relevant idea for investors. Frankly, with the world seemingly poised for a massive conflict, market partici... |
2023-07-24 00:00:00+00:00 | ABBV | IWF, ABBV, TMO, NOW: ETF Outflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $726.3 million dollar outflow -- that's a 1.0% decrease week over week (from 258,550,000 to 255,950,000). ... |
2023-07-23 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-07-21 00:00:00+00:00 | ABBV | 3 High-Yield Dividend Stocks I Plan on Holding Forever | Buy and hold. The first word in this investing strategy is easy to do, but it's a different story for the second one.
Granted, some stocks don't deserve to be held for very long. Management teams can lose investors' confidence or industry dynamics can change. There are many factors that can cause a stock to fall out of... |
2023-07-21 00:00:00+00:00 | ABBV | AbbVie/Genmab's Diffuse Large B-cell Lymphoma Drug A Step Away From Approval In Europe | (RTTNews) - Drug major AbbVie Inc. (ABBV) announced on Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has taken a positive opinion to grant conditional marketing authorization for Epcoritamab to treat relapsed or refractory diffuse large B-cell lymphoma in adults.
T... |
2023-07-21 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-07-20 00:00:00+00:00 | ABBV | Noteworthy Thursday Option Activity: ORLY, REGN, ABBV | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in O'Reilly Automotive, Inc. (Symbol: ORLY), where a total of 2,120 contracts have traded so far, representing approximately 212,000 underlying shares. That amounts to about 53.8% of ORLY's average daily trading volume ... |
2023-07-20 00:00:00+00:00 | ABBV | Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for | The market expects AbbVie (ABBV) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price i... |
2023-07-20 00:00:00+00:00 | ABBV | Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar? | Launched on 06/16/2006, the WisdomTree U.S. High Dividend ETF (DHS) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Wisdomtree. It has amassed assets over $1.16 billion, making it one of the average sized E... |
2023-07-20 00:00:00+00:00 | ABBV | 3 of the Best Dividend Stocks to Buy for Passive Income Growth | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors seeking income from dividend stocks should carefully consider the yield offered. While the average yield in the S&P 500 is 1.56%, some stocks offer double or even triple that amount. The goal is to find reliable blue-chip companies that pay above-... |
2023-07-19 00:00:00+00:00 | ABBV | Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar? | Launched on 10/20/2011, the Schwab U.S. Dividend Equity ETF (SCHD) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Charles Schwab. It has amassed assets over $48.48 billion, making it one of the largest ETF... |
2023-07-19 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-07-18 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights Walmart, AbbVie, Nike, Uber and PayPal | For Immediate Release
Chicago, IL – July 18, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. WMT, AbbVie Inc.... |
2023-07-18 00:00:00+00:00 | ABBV | Softbank-backed Neumora's depression drug cuts symptoms in mid-stage trial | July 18 (Reuters) - Softbank-backed Neumora Therapeutics' experimental drug navacaprant has helped reduce symptoms of depression in patients with moderate-to-severe forms of the disorder in a mid-stage trial, the company said on Tuesday.
Neumora, whose investors include SoftBank Vision Fund and Amgen AMGN.O, said it wo... |
2023-07-17 00:00:00+00:00 | ABBV | 3 Dividend Stocks That Still Make Sense in 2023 | It was hard to find big stock market winners in 2022. But dividend stocks were among the better performers. Dividend-paying stocks give investors a reward for simply holding on to the stock. That money can be used to reinvest into the stock. This can either add to your gains or help to offset your losses.
As many div... |
2023-07-17 00:00:00+00:00 | ABBV | Top Analyst Reports for Walmart, AbbVie & Nike | Monday, July 17, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), AbbVie Inc. (ABBV) and Nike, Inc. (NKE). These research reports have been hand-picked from the roughly 70 reports ... |
2023-07-17 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this drugmaker have returned -1.9%, compared to the Zacks S&P 500 composite's +3.2% change. During thi... |
2023-07-16 00:00:00+00:00 | ABBV | 3 Dividend Growth Stocks to Buy and Hold | Wayne Gretzky probably had no idea how much one thing he said would be repeated through the years. But one of his most famous statements certainly was memorable and worthy of repetition: "I skate to where the puck is going to be, not where it has been."
His idea is applicable in lots of areas. Income investors could ce... |
2023-07-16 00:00:00+00:00 | ABBV | 7 Spectacular High-Yield Dividend Stocks to Buy in July | You don't have to settle for puny dividend income. Thousands of stocks offer dividends. Many of them, though, have dividend yields that don't amount to a hill of beans.
What if you could invest in solid companies with dividends that could really boost your income? The good news is that you can. Here are seven spectacul... |
2023-07-14 00:00:00+00:00 | ABBV | HSBC Initiates Coverage of Abbvie (ABBV) with Buy Recommendation | Fintel reports that on July 14, 2023, HSBC initiated coverage of Abbvie (NYSE:ABBV) with a Buy recommendation.
Analyst Price Forecast Suggests 26.05% Upside
As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The forecasts range from a low of 136.35 to a high of $204.75. The average price target... |
2023-07-14 00:00:00+00:00 | ABBV | Notable ETF Outflow Detected - IWF, V, ABBV, DE | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $364.3 million dollar outflow -- that's a 0.5% decrease week over week (from 259,650,000 to 258,350,000). ... |
2023-07-14 00:00:00+00:00 | ABBV | EXCLUSIVE-MoonLake Immunotherapeutics explores sale-sources | By David Carnevali
July 14 (Reuters) - MoonLake Immunotherapeutics MLTX.O, a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.
The company, which has a market value of $3.1 billion, is working with an investment bank and is ha... |
2023-07-14 00:00:00+00:00 | ABBV | SCHD vs. VYM: Which is the Better Dividend ETF? | The Schwab US Dividend Equity ETF (NYSEARCA:SCHD) and the Vanguard High Dividend Yield Index ETF (NYSEARCA:VYM) are two of the largest and most popular dividend ETFs in the market today. While both have lagged the broader market this year as growth stocks have taken off and left their value and dividend counterparts be... |
2023-07-13 00:00:00+00:00 | ABBV | Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now? | A smart beta exchange traded fund, the WisdomTree U.S. High Dividend ETF (DHS) debuted on 06/16/2006, and offers broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
For a long time now, the ETF industry has been flooded with products based on market capitalization weighte... |
2023-07-13 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | AbbVie (ABBV) closed at $133.59 in the latest trading session, marking a -1.03% move from the prior day. This change lagged the S&P 500's 0.85% gain on the day. At the same time, the Dow added 0.14%, and the tech-heavy Nasdaq gained 5.61%.
Heading into today, shares of the drugmaker had lost 0.92% over the past month, ... |
2023-07-13 00:00:00+00:00 | ABBV | 10 Best Stocks to Buy Now, Stock Market News, and Investing Q&A | The Invesco QQQ Trust (NASDAQ: QQQ) is up over 43% year to date, and investors are wondering what to do next. While large-cap tech names associated with artificial intelligence (AI) have been on a rampage, other stocks haven't been participating in the rally until recently. The below video providesstock market news lon... |
2023-07-12 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-07-12 00:00:00+00:00 | ABBV | Novo Nordisk (NVO) Falls on EMA Safety Review of Obesity Drugs | Nono Nordisk’s NVO GLP-1 receptor agonists, indicated for weight loss and treating type II diabetes, are under scrutiny by the European Medicine Agency ("EMA"). The EMA stated that its safety committee is conducting a review of obesity and diabetes care drugs, which include Ozempic (semaglutide), Saxenda (liraglutide) ... |
2023-07-12 00:00:00+00:00 | ABBV | Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study | Incyte Corporation INCY recently announced positive top-line results from the late-stage TRuE-AD3 study on Opzelura (ruxolitinib cream).
TRuE-AD3 (NCT04921969) is a randomized, double-blind, vehicle-controlled phase III study evaluating the safety and efficacy of ruxolitinib cream compared to vehicle (non-medicated cre... |
2023-07-12 00:00:00+00:00 | ABBV | Noteworthy Wednesday Option Activity: ABBV, CTAS, PARA | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 35,582 contracts have traded so far, representing approximately 3.6 million underlying shares. That amounts to about 56% of ABBV's average daily trading volume over th... |
2023-07-11 00:00:00+00:00 | ABBV | Morgan Stanley Reiterates Abbvie (ABBV) Overweight Recommendation | Fintel reports that on July 11, 2023, Morgan Stanley reiterated coverage of Abbvie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 25.20% Upside
As of July 5, 2023, the average one-year price target for Abbvie is 168.38. The forecasts range from a low of 136.35 to a high of $204.75. The av... |
2023-07-11 00:00:00+00:00 | ABBV | Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval | Roche RHHBY obtained conditional marketing authorization from the European Commission (EC) for its lymphoma drug Columvi (glofitamab).
The drug has been approved for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
The a... |
2023-07-11 00:00:00+00:00 | ABBV | Ex-Dividend Reminder: Buckle, AbbVie and Abbott Laboratories | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.35 on 7/28/23, AbbVie Inc will p... |
2023-07-10 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-07-10 00:00:00+00:00 | ABBV | Cigna to add three Humira biosimilars to drug reimbursement list | July 10 (Reuters) - Cigna Group's Express Scripts said on Monday it would add three Humira biosimilars drugs from German drugmaker Boehringer and Swiss company Novartis to its list of preferred drugs.
The biosimilars of AbbVie's blockbuster arthritis treatment Humira will be included as preferred brands on Express Scri... |
2023-07-10 00:00:00+00:00 | ABBV | Bausch Health (BHC) Secures $600M Financing Facility, Stock Up | Bausch Health Companies Inc. BHC shares were up 8.45% after it announced a crucial development that will significantly enhance its liquidity.
Bausch Health, in collaboration with leading investment firm KKR, has established a non-recourse financing facility worth $600 million. This facility, provided by KKR and its cre... |
2023-07-10 00:00:00+00:00 | ABBV | Novartis (NVS) Entresto Patent Faces Setback, Stock Down | Novartis NVS recently received an unfavorable ruling from the U.S. District Court for the District of Delaware regarding the validity of a patent covering its flagship product, Entresto.
This patent, which includes the combination of sacubitril and valsartan, is set to expire in 2025 with its pediatric exclusivity. Des... |
2023-07-09 00:00:00+00:00 | ABBV | PEP, ABBV, or GM: Which Value Stock Could Offer the Highest Upside? | The fear of the U.S. Federal Reserve resuming interest rate hikes soon has reinforced fears of an impending recession. Investors with a long-term horizon could benefit by looking at attractive value stocks – stocks of companies trading at lower prices than what the fundamentals suggest. Using TipRanks’ Stock Comparison... |
2023-07-08 00:00:00+00:00 | ABBV | 3 No-Brainer Stocks You Can Buy Right Now | Some decisions are hard. Others, however, are so easy that they require much less thought.
Three Motley Fool contributors believe they've found stocks to buy that definitely fall into the latter category. Here's why they think AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX) are no-bra... |
2023-07-08 00:00:00+00:00 | ABBV | ABBV Quantitative Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-07-07 00:00:00+00:00 | ABBV | After Hours Most Active for Jul 7, 2023 : INTC, AAPL, BAC, KO, TLT, QQQ, GOOGL, PLTR, RIVN, ABBV, HL, RLJ | The NASDAQ 100 After Hours Indicator is up 3.48 to 15,040.33. The total After hours volume is currently 80,191,351 shares traded.
The following are the most active stocks for the after hours session:
Intel Corporation (INTC) is +0.01 at $31.86, with 5,468,000 shares traded. INTC's current last sale is 101.14% of the ... |
2023-07-07 00:00:00+00:00 | ABBV | 2 Struggling Dividend Growth Stocks That Could Make You Richer | Despite lingering economic issues, the broader stock market has recovered this year. But some companies are failing to keep up for a variety of reasons. Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN), two drugmakers that have significantly underperformed the stock market this year. Both healthcare giants are encount... |
2023-07-07 00:00:00+00:00 | ABBV | Why Dividend Stocks Should Be a Key Part of Your Retirement Plan | Americans believe they need to save $1.3 million for retirement, according to a recent study by Northwestern Mutual. In most cases, people are well short of that goal and it may simply not be attainable.
But one way that you can bolster your financial situation is by investing in dividend stocks. Here's why they should... |
2023-07-07 00:00:00+00:00 | ABBV | The 3 Best Dividend Stocks to Buy in July | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividend stocks continue to be highly sought after, especially among investors who seek to generate income. Retirees appreciate the regular payments provided by stocks that offer dividends to their shareholders. That said, not all stocks pay dividends, and ... |
2023-07-06 00:00:00+00:00 | ABBV | Is AbbVie's Dividend Yield Safe? | AbbVie (NYSE: ABBV) is a leading pharmaceutical company that rewards its shareholders with a generous dividend policy. The company has a history of increasing its dividends for more than 50 years in a row, earning it the status of Dividend King. AbbVie also sports one of the highest dividend yields within its peer grou... |
2023-07-06 00:00:00+00:00 | ABBV | AbbVie trims full-year profit forecast on higher R&D expenses | Adds second quarter forecast in paragraph 5
July 6 (Reuters) - AbbVie Inc ABBV.N cut its full-year profit forecast on Thursday, citing $280 million in milestone and in-process research and development expenses during the second quarter.
The company now expects adjusted profit between $10.57 and $10.97 per share, compar... |
2023-07-06 00:00:00+00:00 | ABBV | AbbVie trims full-year profit forecast due to higher R&D expenses | July 6 (Reuters) - AbbVie Inc ABBV.N cut full-year profit forecast due to unfavorable impact from R&D and milestone expenses, the drugmaker said on Thursday.
The company now expects adjusted profit between $10.57 and $10.97 per share, compared with $10.72 to $11.12 per share it previously expected.
(Reporting by Khushi... |
2023-07-06 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Moves -0.27%: What You Should Know | AbbVie (ABBV) closed the most recent trading day at $137.25, moving -0.27% from the previous trading session. This move was narrower than the S&P 500's daily loss of 0.79%. At the same time, the Dow lost 1.07%, and the tech-heavy Nasdaq lost 2.71%.
Coming into today, shares of the drugmaker had gained 0.82% in the past... |
2023-07-06 00:00:00+00:00 | ABBV | Got $5,000? These Are 3 of the Best Stocks to Buy in July | If you're looking to invest in the stock market this summer, there are many great options out there to consider. Whether you're after dividends, growth, or simply long-term stability, there are stocks that can help you achieve those goals -- without having to pay a huge premium to do so.
AbbVie (NYSE: ABBV), Verizon Co... |
2023-07-06 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Shares of this drugmaker have returned +0.8% over the past month versus the Zacks S&P 500 composite's +4.2% change. The Zacks Large C... |
2023-07-06 00:00:00+00:00 | ABBV | Pre-Market Most Active for Jul 6, 2023 : SQQQ, TQQQ, TSLA, CRBU, RIVN, LCID, FCX, NIO, GENI, ABBV, CCL, PLTR | The NASDAQ 100 Pre-Market Indicator is down -116.62 to 15,087.16. The total Pre-Market volume is currently 30,703,363 shares traded.
The following are the most active stocks for the pre-market session:
ProShares UltraPro Short QQQ (SQQQ) is +0.3801 at $19.17, with 3,110,791 shares traded. This represents a 3.45% incr... |
2023-07-06 00:00:00+00:00 | ABBV | Sarepta (SRPT) Sells Priority Review Voucher for $102M | Sarepta SRPT announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (“PRV”) for $102 million.
The monetization of the PRV will enable management to develop more transformative therapies as it plans to invest the proceeds into the company’s research and development (“R&D”) efforts.
Ye... |
2023-07-05 00:00:00+00:00 | ABBV | The 7 Best Forever Stocks to Buy for July 2023 | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
With the latest encouraging read on inflation sending the market on a high to end the first half of this year, the idea of acquiring the best forever stocks may seem overly cautious. After all, with sentiment strong on apparently justifiable reasons, invest... |
2023-07-05 00:00:00+00:00 | ABBV | Mark Cuban's online pharmacy set to launch Humira biosimilar | By Michael Erman
July 5 (Reuters) - Mark Cuban Cost Plus Drugs, an online pharmacy launched by the billionaire to sell drugs directly to customers at low prices, should soon begin selling Coherus BioSciences's CHRS.O biosimilar version of AbbVie Inc's ABBV.N blockbuster rheumatoid arthritis drug Humira, Cuban said on W... |
2023-07-05 00:00:00+00:00 | ABBV | Noteworthy ETF Inflows: SSO, CVX, COST, ABBV | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $134.1 million dollar inflow -- that's a 3.2% increase week over week in outstanding units (from 71,350,000 to 73,6... |
2023-07-05 00:00:00+00:00 | ABBV | Celltrion launches biosimilar of AbbVie's blockbuster drug Humira in US | July 5 (Reuters) - South Korea's Celltrion Healthcare 091990.KQhas launched a copycat version to AbbVie Inc's ABBV.N Humira at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the U.S.
The biosimilar, Yuflyma, became available for sale in the U.S. on Sunday, the co... |
2023-07-04 00:00:00+00:00 | ABBV | 3 Spectacular Dividend Stocks to Buy in July | A new month is here. And with it comes a new opportunity to invest in spectacular dividend stocks.
Three Motley Fool contributors think they know some great candidates to buy in July. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Johnson & Johnson (NYSE: JNJ).
High-yield dividend roy... |
2023-07-04 00:00:00+00:00 | ABBV | AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results | AstraZeneca AZN reported results from an interim analysis of the phase III TROPION-Lung01 study evaluating datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) treated with at least one prior therapy.
The company reported mixed results from the TROPION-L... |
2023-07-03 00:00:00+00:00 | ABBV | 3 Magnificent Dividend Stocks to Buy Hand Over Fist in July | Temperatures are rising. And so are concerns about what's next for the stock market. The answer to the former issue is air conditioning and/or a cool swim. The latter is more challenging.
However, one possibility is to invest in stocks that pay you to own them and that have solid long-term prospects. With that in mind,... |
2023-07-03 00:00:00+00:00 | ABBV | Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus | Novartis NVS, a leading pharmaceutical company, recently made a strategic decision to divest its “front of eye” ophthalmology assets to Bausch + Lomb BLCO, a global eye health company.
Xiidra, the first approved prescription treatment for dry eye disease, and SAF312, a first-in-class therapy for chronic ocular surface ... |
2023-07-03 00:00:00+00:00 | ABBV | Will Eli Lilly Stock Continue To Rise After 40% Gains In The Ongoing Inflation Shock? | Eli Lilly stock (NYSE: LLY) currently trades at $459 per share, roughly 150% above its level in March 2021, and its valuation looks stretched now, in our view. LLY saw its stock trading at around $324 in late June 2022, just before the Fed started increasing rates, and is now 40% above that level, outperforming the bro... |
2023-07-03 00:00:00+00:00 | ABBV | Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys | Drug companies Merck (NYSE: MRK) and AbbVie (NYSE: ABBV) have been two of the best pharmaceutical investments, easily delivering better total returns than the S&P 500 average over the past three, five, and 10 years.
However, as it is often said, past performance is no guarantee of future success. Both companies are com... |
2023-07-03 00:00:00+00:00 | ABBV | Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira | Adds background in paragraphs 2-5
July 3 (Reuters) - Coherus BioSciences CHRS.O said on Monday it has launched a copycat version of AbbVie's ABBV.N Humira in the United States at a discount of over 85% to the blockbuster arthritis drug.
Coherus is the latest to launch the biosimilar to Humira in the U.S. market this mo... |
2023-07-03 00:00:00+00:00 | ABBV | India's Biocon Biologics launches biosimilar for AbbVie's Humira in US | July 3 (Reuters) - India's Biocon Biologics BIOC.NS said on Monday it has launched a biosimilar version of AbbVie's ABBV.N blockbuster rheumatoid arthritis drug Humira in the United States.
The launch of the copycat version, branded as Hulio, adds to a list of biosimilars introduced by drugmakers on Monday by Coherus B... |
2023-07-02 00:00:00+00:00 | ABBV | Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators? | Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB), was recently given the green light by the Food and Drug Administration to be used as a treatment for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
What could this news mean for patients diagnosed ... |
2023-07-02 00:00:00+00:00 | ABBV | 10 Stocks You Can Buy Right Now With Dividend Yields of Over 4% | Have you ever received a check in the mail for an amount that was less than the cost of the stamp? The effort to send the check really wasn't worth the trouble.
In a similar vein, some stocks offer dividends that are so puny that they don't help investors much. However, there are others that definitely make a differenc... |
2023-07-01 00:00:00+00:00 | ABBV | Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount | By Patrick Wingrove
July 1 (Reuters) - Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie’s ABBV.N blockbuster arthritis drug Humira, while two other drugmakers entered the market with much more modest discounts to the branded medicine's list p... |
2023-07-01 00:00:00+00:00 | ABBV | Sandoz launches rival version of AbbVie's arthritis drug Humira | July 1 (Reuters) - Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's ABBV.N big selling arthritis treatment Humira, adding to U.S. competition for the drug that started in January.
The Novartis NOVN.S-owned company said its drug, Hyrimoz, will be priced at a 5% discount off Hu... |
2023-06-30 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-30 00:00:00+00:00 | ABBV | Immunome Pops on Compelling Merger Agreement | Though the Thursday session ended on a soft note for Wall Street, aspirational biopharmaceutical firm Immunome (US:IMNM) enjoyed a dramatic leap higher, with INMN stock gaining over 30% against the prior day’s close. Undergirding the extreme positive sentiment was a merger agreement with Morphimmune, a privately held b... |
2023-06-30 00:00:00+00:00 | ABBV | ANALYSIS-New Humira rivals likely to hit US market with small discounts in July | By Patrick Wingrove
NEW YORK, June 30 (Reuters) - At least four drugmakers are expected to launch new copycat versions of AbbVie's ABBV.N top-selling rheumatoid arthritis drug, Humira, over the next week, but experts expect little change in prices for the treatment even with the new competition.
Drugmakers Boehringer I... |
2023-06-30 00:00:00+00:00 | ABBV | Bausch + Lomb to buy Novartis dry-eye drug for $1.75 bln - WSJ | Adds background throughout
June 30 (Reuters) - Bausch + Lomb Corp BLCO.TO will purchase a dry-eye drug from Swiss pharma company Novartis NOVN.S for $1.75 billion, the Wall Street Journal reported on Friday, as the contact lens maker seeks to capitalise on a growing market for the disease's treatment.
Acquisition of th... |
2023-06-30 00:00:00+00:00 | ABBV | Notable Friday Option Activity: ABBV, TWLO, UNH | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 34,753 contracts have traded so far, representing approximately 3.5 million underlying shares. That amounts to about 55% of ABBV's average daily trading volume over th... |
2023-06-30 00:00:00+00:00 | ABBV | Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly | Shares of Sigilon Therapeutics SGTX surged 440.9% on Jun 29, after the company announced that it has signed a definitive agreement with Eli Lilly LLY. Lilly will acquire all the outstanding shares of Sigilon for an upfront payment of $14.92 per share in cash, aggregating to $34.6 million.
Existing shareholders will als... |
2023-06-30 00:00:00+00:00 | ABBV | The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023 | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Pharmaceutical stocks have not shared in this year’s bull rally. Year to date, the S&P Pharmaceuticals Select Industry index is down 1% while the benchmark S&P 500 index has gained 15%. After a strong run during the pandemic when Covid-19 vaccines started b... |
2023-06-30 00:00:00+00:00 | ABBV | Why Shares of Alvotech Are Jumping Friday | What happened
Shares of biosimilar pharmaceutical maker Alvotech (NASDAQ: ALVO) were up more than 11% as of noon on Friday. On Thursday, it plunged more than 6% after the company announced it had received a complete response letter (CRL) from the Food and Drug Administration (FDA) regarding one of its therapies.
So wha... |
2023-06-29 00:00:00+00:00 | ABBV | 5 High-Yielding Dividend Stocks That Are Bargain Buys | If you're in search of bargain stocks to buy, the healthcare industry is a great place to start looking. The tech sector has been attracting more attention of late due to the hype around artificial intelligence (AI).
But that has left some pretty good deals overlooked in the healthcare sector. Among them are Johnson & ... |
2023-06-29 00:00:00+00:00 | ABBV | 7 Best Dividend Stocks to Buy Now in July 2023 | Today, I provide my seven best dividend stocks to buy for the month of July 2023. Dividend stocks are a great way to add balance and passive income to a long-term investing portfolio. Compound interest is often called the eighth wonder of the world, and dividends are a great way to accelerate your wealth.
Two of my fav... |
2023-06-29 00:00:00+00:00 | ABBV | 3 Dividend Kings Yielding Royal Sums | If you are focused on investing for income look no further. Dividend Kings are stocks that have raised their dividends for at least 50 consecutive years, a feat made possible by uber-consistent business management and commitment to shareholders.
These are stocks that have not only survived a huge range of different adv... |
2023-06-29 00:00:00+00:00 | ABBV | FXH's Holdings Imply 19% Gain Potential | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Health Care AlphaDE... |
2023-06-29 00:00:00+00:00 | ABBV | 5 Dividend Aristocrats Where Analysts See Capital Gains | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... |
2023-06-28 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights Novo Nordisk, Home Depot, Disney, AbbVie and Automatic Data Processing | For Immediate Release
Chicago, IL – June 28, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Novo Nordisk A/S NVO, The Hom... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.